• Ligand to Acquire Pfenex americanpharmaceuticalreview
    August 19, 2020
    Ligand Pharmaceuticals and Pfenex announced the signing of a definitive agreement for Ligand to acquire all outstanding shares of Pfenex for $12.00 per share in cash or $438 million in equity value on a fully diluted basis.
  • Biological E. acquires Akorn India expresspharma
    August 18, 2020
    The timing of this acquisition is fortuitous as it will immediately allow us to expand our capacity to manufacture our investigational COVID-19 vaccine, said the company.
  • Bayer to acquire KaNDy Therapeutics with $425 million upfront payment europeanpharmaceuticalreview
    August 17, 2020
    Bayer will acquire KaNDy Therapeutics Ltd for an upfront cost of $425 million to expand its drug development pipeline in women’s healthcare.
  • Ligand Pharmaceuticals agrees to acquire Pfenex for $516m pharmaceutical-technology
    August 12, 2020
    Ligand Pharmaceuticals has entered into a definitive agreement to acquire development and licencing biotechnology firm Pfenex in a deal valued at approximately $516m.
  • Rafarma to be Acquired by R. & D. Biocogency Laboratories americanpharmaceuticalreview
    August 07, 2020
    Rafarma Pharmaceuticals has reached an agreement to be acquired by R. & D. Biocogency Laboratories. Under the agreed terms, Bio-cogency will acquire majority control of Rafarma Pharmaceuticals upon completion of Biocogency’s transition to GAAP ...
  • Sun Pharma arm to acquire Aquinox Pharmaceuticals (Canada) expresspharma
    July 30, 2020
    The cost of acquisition is about $8.2 million.
  • Gilead to acquire stake in Tizona Therapeutics for $300n pharmaceutical-technology
    July 23, 2020
    Gilead Sciences is set to acquire a 49.9% equity interest in cancer immunotherapies maker Tizona Therapeutics through an investment of $300m.
  • Nexelis Acquires AIT Bioscience contractpharma
    July 23, 2020
    AIT Bioscience’s advanced testing capacity bolsters service offering in the bioanalytical segment.
  • Mydecine Innovations, NeuroPharm Sign Acquisition Agreement americanpharmaceuticalreview
    July 22, 2020
    Mydecine Innovations has entered into a definitive share exchange agreement for the acquisition of 100% of NeuroPharm, a Canadian-based developer of natural psychedelic-based treatments for mental health disorders in the Canadian and United States ...
  • Grifols to acquire GC Pharma’s plasma fractionation facility for $460m pharmaceutical-technology
    July 22, 2020
    Plasma-derived medicines company Grifols has executed purchase arrangements with South Korean-based GC Pharma to acquire a plasma fractionation facility in Montreal, Canada for $460m.
PharmaSources Customer Service